Ankylosing Spondylitis
Featured Article
No biologic strategies in treatment guidelines for ankylosing spondylitis were cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year.
Patients with ankylosing spondylitis who switch or discontinue their biologic within a year of starting it have higher health care utilization and medical costs compared with patients who stay with…
Researchers found a positive association between the use of antidepressant and anxiolytic medication with both the introduction and switching of bDMARDs.